Health ❯ Healthcare ❯ Medical Research ❯ Cancer Research

Immunotherapy

Tumours Secrete PRDX1 Antioxidant to Silence Cancer‑Killing T Cells

Preclinical experiments show removing the extracellular antioxidant restores T cell activation and can make resistant tumours respond to checkpoint immunotherapy.

6 ARTICLES

3mo ago

CAR‑T Cells Targeting GPNMB Eradicate Glioblastoma in Preclinical Models

3 ARTICLES

4mo ago

Phase 1 TCER IMA401 Shows Early Safety and Tumor Responses in Solid Cancers

3 ARTICLES

5mo ago

Preclinical Combo Reprograms Tumor Immunity to Overcome Colorectal Cancer Resistance

5 ARTICLES

8mo ago

CD70-Targeted HIT Cells Eradicate Solid Tumors in Mice

3 ARTICLES

9mo ago

New CAR T Strategy Targets Tumor Macrophages, Triggers Antitumor Immunity in Mice

4 ARTICLES

11mo ago

Study Identifies TSP‑1–CD47 Signal That Drives T‑Cell Exhaustion in Cancer

5 ARTICLES

last yr.

mRNA COVID Vaccines Tied to Longer Survival With Checkpoint Immunotherapy, Nature Study Reports

29 ARTICLES

last yr.

mRNA COVID Vaccines Linked to Longer Survival With Checkpoint Immunotherapy, Peer‑Reviewed Study Finds

13 ARTICLES

last yr.

mRNA COVID Vaccination Linked to Longer Survival With Cancer Immunotherapy, Data Presented at ESMO

6 ARTICLES

last yr.

Nanoparticle 'Super Adjuvant' Vaccine Blocks Multiple Cancers in Mice

5 ARTICLES

last yr.

UMass Amherst Dual-Adjuvant Nanoparticle Vaccine Blocks Tumors and Metastasis in Mice

7 ARTICLES

last yr.

Dual-Adjuvant Nanoparticle Vaccine Prevents Multiple Cancers in Mice, Blocks Metastasis

6 ARTICLES

last yr.

Engineered CAR-T Cells Target PD-L1 to Deliver IL-12 at Tumors, Showing Solid-Tumor Gains in Mice

3 ARTICLES

last yr.

Glycan-Targeting ‘GlyTR’ Therapy Kills Diverse Cancers in Preclinical Tests

5 ARTICLES

last yr.

Tumor-Induced Nerve Injury Identified as Driver of Anti–PD-1 Resistance

3 ARTICLES

last yr.

KRAS-Targeted Vaccine Shows Robust Immune Response, Longer-Than-Expected Survival in Pancreatic and Colorectal Cancer Trial

3 ARTICLES

last yr.

AI-Informed Pipeline Accelerates Bi-Specific CAR-T Design and Clears Tumors in Mice

4 ARTICLES

last yr.

mRNA Neoantigen Vaccine Amplifies Anti-PD-1 Immunity and Suppresses Gastric Cancer Spread in Mice

17 ARTICLES

last yr.

Off-The-Shelf KRAS Vaccine Yields Robust T-Cell Responses and Survival Benefit

Immunotherapy

Tumours Secrete PRDX1 Antioxidant to Silence Cancer‑Killing T Cells

CAR‑T Cells Targeting GPNMB Eradicate Glioblastoma in Preclinical Models

Phase 1 TCER IMA401 Shows Early Safety and Tumor Responses in Solid Cancers

Preclinical Combo Reprograms Tumor Immunity to Overcome Colorectal Cancer Resistance

CD70-Targeted HIT Cells Eradicate Solid Tumors in Mice

New CAR T Strategy Targets Tumor Macrophages, Triggers Antitumor Immunity in Mice

Study Identifies TSP‑1–CD47 Signal That Drives T‑Cell Exhaustion in Cancer

mRNA COVID Vaccines Tied to Longer Survival With Checkpoint Immunotherapy, Nature Study Reports

mRNA COVID Vaccines Linked to Longer Survival With Checkpoint Immunotherapy, Peer‑Reviewed Study Finds

mRNA COVID Vaccination Linked to Longer Survival With Cancer Immunotherapy, Data Presented at ESMO

Never miss stories about

Immunotherapy

Nanoparticle 'Super Adjuvant' Vaccine Blocks Multiple Cancers in Mice

UMass Amherst Dual-Adjuvant Nanoparticle Vaccine Blocks Tumors and Metastasis in Mice

Dual-Adjuvant Nanoparticle Vaccine Prevents Multiple Cancers in Mice, Blocks Metastasis

Engineered CAR-T Cells Target PD-L1 to Deliver IL-12 at Tumors, Showing Solid-Tumor Gains in Mice

Glycan-Targeting ‘GlyTR’ Therapy Kills Diverse Cancers in Preclinical Tests

Tumor-Induced Nerve Injury Identified as Driver of Anti–PD-1 Resistance

KRAS-Targeted Vaccine Shows Robust Immune Response, Longer-Than-Expected Survival in Pancreatic and Colorectal Cancer Trial

AI-Informed Pipeline Accelerates Bi-Specific CAR-T Design and Clears Tumors in Mice

mRNA Neoantigen Vaccine Amplifies Anti-PD-1 Immunity and Suppresses Gastric Cancer Spread in Mice

Off-The-Shelf KRAS Vaccine Yields Robust T-Cell Responses and Survival Benefit

Never miss stories about

Immunotherapy